Navigation Links
Antibody extends life of mice with breast cancer

A monoclonal antibody developed by researchers at the University at Buffalo has been shown to extend significantly the survival of mice with human breast-cancer tumors and to inhibit the cancer's spread to the lungs in the animals by more than 50 percent.

The antibody, named JAA-F11, targets a particular disaccharide, an antigen known as TF-Ag, which aids the adhesion and spread of certain cancer cells. While the antibody did not kill the cancer cells, it blocked stages of cancer-cell growth that allow the cells to adhere to organ tissue, the research showed.

Results of the research appeared in the November 2006 issue of the journal Neoplasia.

Mice with breast-cancer tumors that received the antibody had a median survival time of 72 days, compared to 57 days for the animals that did not receive JAA-F11, the study found. In addition, exposing cultures of tumor cells to the antibody inhibited cell growth by a statistically significant 16 percent.

Kate Rittenhouse-Olson, Ph.D., associate professor of clinical and laboratory sciences in the UB School of Medicine and Biomedical Sciences, is senior author on the study.

"This antibody binds with a carbohydrate on the tumor cell surface that is involved in adhesion of the cell during the metastatic process," said Rittenhouse-Olson. "Not only would drugs attached to the antibody JAA-F11 bind to the tumor cell surface to direct their cytotoxic effect, but the binding of the antibody itself would block the cell from metastasizing."

The antibody was tested using in vitro models of tumor cell growth, in assays to determine its ability to damage or kill cells (cytotoxicity), in various models of cancer metastasis, and, finally, in mice with metastatic breast cancer.

"In addition to providing a survival advantage," said Rittenhouse-Olson, "JAA-F11 immunotherapy reduced the metastatic tumor burden significantly, reflected by both a dramatic decline in the overall incidence of spontaneous metastasis to the lung -- 88 percent to 47 percent -- and fewer macroscopic metastatic lesions."

The research group currently is determining if JAA-F11 could increase the effectiveness of existing cancer drugs, she said, as well as studying the possibility of using the antibody as a vehicle for the targeted delivery of drugs to aid cancer diagnosis and therapy.


'"/>

Source:University at Buffalo


Related biology news :

1. Antibody signal may redirect inflammation to fuel cancer
2. Antibody therapy prevents type 1 diabetes in mice
3. Combined treatment extends life expectancy for lung cancer patients
4. Single molecule extends fat mice lives by reversing gene pathways associated with disease in obese
5. Viral DNA sequence a possible trigger for breast cancer
6. Used in a new way, RNA interference permanently silences key breast cancer gene
7. Biomarkers isolated from saliva successfully predict oral and breast cancer
8. Study reveals dramatic difference between breast cancers in US and Africa
9. Compounds in plastic packaging act as environmental estrogens altering breast genes
10. Alcohol consumption disrupts breastfeeding hormones
11. VCU Massey Cancer Center study shows enzyme linked to spread of breast cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
(Date:12/15/2016)...  There is much more to innovative access systems ... Continental will demonstrate the intelligence of today,s solutions at ... Through the combination of the keyless entry and start ... the international technology company is opening up new possibilities ... "The integration of biometric elements brings our expertise ...
(Date:12/8/2016)... -- Market Research Future published a half cooked research report on ... and Service Market is expected to grow over the CAGR of ... ... Mobile Biometric Security and Service Market is increasing ... authentication and security from unwanted cyber threats. The increasing use of ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... and HOUSTON , Jan. 19, ... today announced the formation of its Medical/Clinical Advisory ... and industry veterans who enhance the range and ... accelerates development of its novel prenatal diagnostic tests.  ... clinical and strategic guidance for the company,s product ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... pharmaceutical research and development (R&D), today announced the launch of Data ... interpretation for the rapidly evolving field of precision medicine. , Data ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... January 18, 2017 , ... LabRoots ... scientists from around the world, was today awarded the "Best Science & Technology ... entirely on merit and decided upon by a dedicated team of researchers and ...
Breaking Biology Technology: